Cidara stock up on revised trial for flu drug (CDTX:NASDAQ)

Core Insights - Cidara Therapeutics announced an accelerated timeline for a Phase 3 registrational trial for its experimental flu therapy CD388, leading to a ~15% increase in stock price [2] Company Summary - Cidara Therapeutics is focusing on the development of CD388, an experimental therapy aimed at treating influenza [2] - The update on the trial timeline followed a successful End-of-Phase 2 meeting with regulatory authorities [2]